Compare AJANTA PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STRIDES PHARMA SCIENCE AJANTA PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 27.5 43.7 62.8% View Chart
P/BV x 7.6 2.0 373.8% View Chart
Dividend Yield % 0.5 0.2 194.0%  

Financials

 AJANTA PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
AJANTA PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,4221,147 124.0%   
Low Rs898642 139.8%   
Sales per share (Unadj.) Rs233.5317.2 73.6%  
Earnings per share (Unadj.) Rs44.07.8 560.4%  
Cash flow per share (Unadj.) Rs52.225.1 208.1%  
Dividends per share (Unadj.) Rs9.002.00 450.0%  
Dividend yield (eoy) %0.80.2 347.1%  
Book value per share (Unadj.) Rs255.1274.3 93.0%  
Shares outstanding (eoy) m88.0289.50 98.3%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.8 176.1%   
Avg P/E ratio x26.4114.0 23.1%  
P/CF ratio (eoy) x22.235.7 62.3%  
Price / Book Value ratio x4.53.3 139.4%  
Dividend payout %20.525.5 80.3%   
Avg Mkt Cap Rs m102,08180,058 127.5%   
No. of employees `0006.82.5 271.2%   
Total wages/salary Rs m4,3074,341 99.2%   
Avg. sales/employee Rs Th3,022.611,325.8 26.7%   
Avg. wages/employee Rs Th633.41,731.4 36.6%   
Avg. net profit/employee Rs Th569.1280.1 203.2%   
INCOME DATA
Net Sales Rs m20,55428,394 72.4%  
Other income Rs m211941 22.4%   
Total revenues Rs m20,76529,334 70.8%   
Gross profit Rs m5,6643,965 142.8%  
Depreciation Rs m7211,540 46.8%   
Interest Rs m121,962 0.6%   
Profit before tax Rs m5,1431,403 366.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,27397 1,308.3%   
Profit after tax Rs m3,870702 551.2%  
Gross profit margin %27.614.0 197.3%  
Effective tax rate %24.86.9 357.0%   
Net profit margin %18.82.5 761.4%  
BALANCE SHEET DATA
Current assets Rs m11,81224,836 47.6%   
Current liabilities Rs m3,77618,993 19.9%   
Net working cap to sales %39.120.6 190.0%  
Current ratio x3.11.3 239.2%  
Inventory Days Days7771 109.0%  
Debtors Days Days82113 72.0%  
Net fixed assets Rs m14,39834,289 42.0%   
Share capital Rs m175895 19.6%   
"Free" reserves Rs m22,27723,651 94.2%   
Net worth Rs m22,45224,546 91.5%   
Long term debt Rs m715,513 0.0%   
Total assets Rs m26,96265,437 41.2%  
Interest coverage x444.31.7 25,908.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.4 175.7%   
Return on assets %14.44.1 353.5%  
Return on equity %17.22.9 602.6%  
Return on capital %23.06.9 332.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68215,697 68.0%   
Fx outflow Rs m2,102735 285.8%   
Net fx Rs m8,58014,962 57.3%   
CASH FLOW
From Operations Rs m3,7481,871 200.3%  
From Investments Rs m-2,2285,826 -38.2%  
From Financial Activity Rs m-1,475-10,157 14.5%  
Net Cashflow Rs m45-2,615 -1.7%  

Share Holding

Indian Promoters % 73.8 27.7 266.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 37.8 4.1%  
FIIs % 7.6 8.6 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.9 65.6%  
Shareholders   20,968 56,241 37.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 200 Points Lower, Dow Futures Down by 59 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 240 points, down 0.5% at 49,262 levels.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 11, 2021 03:36 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS